Notably, COVID-19 patients characterized by anti-CL antibodies are also characterized by having anti-β2-glycoprotein I (aβ2-GPI) IgG and IgM (39% and up to 34% of patients, respectively) and up to 12% are also positive for lupus anticoagulant (LA) antibodies [96], another recognized risk factor for coagulopathies. The gene discussed is GPI; the disease is COVID-19.